Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIA or IIIB non-small cell lung cancer (NSCLC) that is not caused by EGFR or ALK gene changes.
- You are between 18 and 74 years old.
- You are healthy enough to have surgery (your heart and lungs work well for an operation).
- You have not had immunotherapy (like a checkpoint inhibitor) or chest radiation before.
- You agree to use effective birth control during and for a time after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This trial gives a combination of chemotherapy and durvalumab (an immunotherapy drug) before surgery or radiation, then durvalumab alone afterward. It aims to shrink the tumor and improve outcomes for people with stage III non-small cell lung cancer that is borderline resectable.
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests whether giving a combination of an immunotherapy drug (serplulimab) and chemotherapy before any surgery can help shrink tumors in people with stage III lung cancer that can't be removed. The goal is to make the cancer easier to treat and improve outcomes.
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Hear when a new Lung Cancer Non-Small Cell Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.